141 related articles for article (PubMed ID: 33015524)
1. Systematic Assessment of Tumor Purity and Its Clinical Implications.
Haider S; Tyekucheva S; Prandi D; Fox NS; Ahn J; Xu AW; Pantazi A; Park PJ; Laird PW; Sander C; Wang W; Demichelis F; Loda M; Boutros PC;
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015524
[TBL] [Abstract][Full Text] [Related]
2. A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles.
Wang L; Sebra RP; Sfakianos JP; Allette K; Wang W; Yoo S; Bhardwaj N; Schadt EE; Yao X; Galsky MD; Zhu J
Genome Med; 2020 Feb; 12(1):24. PubMed ID: 32111252
[TBL] [Abstract][Full Text] [Related]
3. PUREE: accurate pan-cancer tumor purity estimation from gene expression data.
Revkov E; Kulshrestha T; Sung KW; Skanderup AJ
Commun Biol; 2023 Apr; 6(1):394. PubMed ID: 37041233
[TBL] [Abstract][Full Text] [Related]
4. Prediction of tumor purity from gene expression data using machine learning.
Koo B; Rhee JK
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33954576
[TBL] [Abstract][Full Text] [Related]
5. Not every estimate counts - evaluation of cell composition estimation approaches in brain bulk tissue data.
Toker L; Nido GS; Tzoulis C
Genome Med; 2023 Jun; 15(1):41. PubMed ID: 37287013
[TBL] [Abstract][Full Text] [Related]
6. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.
Cao S; Wang JR; Ji S; Yang P; Dai Y; Guo S; Montierth MD; Shen JP; Zhao X; Chen J; Lee JJ; Guerrero PA; Spetsieris N; Engedal N; Taavitsainen S; Yu K; Livingstone J; Bhandari V; Hubert SM; Daw NC; Futreal PA; Efstathiou E; Lim B; Viale A; Zhang J; Nykter M; Czerniak BA; Brown PH; Swanton C; Msaouel P; Maitra A; Kopetz S; Campbell P; Speed TP; Boutros PC; Zhu H; Urbanucci A; Demeulemeester J; Van Loo P; Wang W
Nat Biotechnol; 2022 Nov; 40(11):1624-1633. PubMed ID: 35697807
[TBL] [Abstract][Full Text] [Related]
7. Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study.
Oner MU; Chen J; Revkov E; James A; Heng SY; Kaya AN; Alvarez JJS; Takano A; Cheng XM; Lim TKH; Tan DSW; Zhai W; Skanderup AJ; Sung WK; Lee HK
Patterns (N Y); 2022 Feb; 3(2):100399. PubMed ID: 35199060
[TBL] [Abstract][Full Text] [Related]
8. Weakly-supervised tumor purity prediction from frozen H&E stained slides.
Brendel M; Getseva V; Assaad MA; Sigouros M; Sigaras A; Kane T; Khosravi P; Mosquera JM; Elemento O; Hajirasouliha I
EBioMedicine; 2022 Jun; 80():104067. PubMed ID: 35644123
[TBL] [Abstract][Full Text] [Related]
9. Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types.
Rhee JK; Jung YC; Kim KR; Yoo J; Kim J; Lee YJ; Ko YH; Lee HH; Cho BC; Kim TM
Cancer Immunol Res; 2018 Jan; 6(1):87-97. PubMed ID: 29141981
[TBL] [Abstract][Full Text] [Related]
10. RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regression.
Johann PD; Jäger N; Pfister SM; Sill M
BMC Bioinformatics; 2019 Aug; 20(1):428. PubMed ID: 31419933
[TBL] [Abstract][Full Text] [Related]
11. Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach.
Patel NM; Jo H; Eberhard DA; Yin X; Hayward MC; Stein MK; Hayes DN; Grilley-Olson JE
Appl Immunohistochem Mol Morphol; 2019; 27(10):764-772. PubMed ID: 30102605
[TBL] [Abstract][Full Text] [Related]
12. Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.
Zhao B; Xia Y; Yang F; Wang Y; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Mol Med; 2022 Mar; 28(1):34. PubMed ID: 35287567
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
Nederlof I; De Bortoli D; Bareche Y; Nguyen B; de Maaker M; Hooijer GKJ; Buisseret L; Kok M; Smid M; Van den Eynden GGGM; Brinkman AB; Hudecek J; Koster J; Sotiriou C; Larsimont D; Martens JWM; van de Vijver MJ; Horlings HM; Salgado R; Biganzoli E; Desmedt C
Breast Cancer Res; 2019 Dec; 21(1):151. PubMed ID: 31878981
[TBL] [Abstract][Full Text] [Related]
14. An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples.
Yadav VK; De S
Brief Bioinform; 2015 Mar; 16(2):232-41. PubMed ID: 24562872
[TBL] [Abstract][Full Text] [Related]
15. Inferring tumour purity and stromal and immune cell admixture from expression data.
Yoshihara K; Shahmoradgoli M; Martínez E; Vegesna R; Kim H; Torres-Garcia W; Treviño V; Shen H; Laird PW; Levine DA; Carter SL; Getz G; Stemke-Hale K; Mills GB; Verhaak RG
Nat Commun; 2013; 4():2612. PubMed ID: 24113773
[TBL] [Abstract][Full Text] [Related]
16. Systematic pan-cancer analysis of tumour purity.
Aran D; Sirota M; Butte AJ
Nat Commun; 2015 Dec; 6():8971. PubMed ID: 26634437
[TBL] [Abstract][Full Text] [Related]
17. Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures.
Xiong Y; Xiong Z; Cao H; Li C; Wanggou S; Li X
Cancer Cell Int; 2020; 20():37. PubMed ID: 32021566
[TBL] [Abstract][Full Text] [Related]
18. Improved cell composition deconvolution method of bulk gene expression profiles to quantify subsets of immune cells.
Chiu YJ; Hsieh YH; Huang YH
BMC Med Genomics; 2019 Dec; 12(Suppl 8):169. PubMed ID: 31856824
[TBL] [Abstract][Full Text] [Related]
19. Tumor Purity as an Underlying Key Factor in Glioma.
Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A
Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819
[No Abstract] [Full Text] [Related]
20. Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer.
Mao Y; Feng Q; Zheng P; Yang L; Liu T; Xu Y; Zhu D; Chang W; Ji M; Ren L; Wei Y; He G; Xu J
Cancer Manag Res; 2018; 10():3569-3577. PubMed ID: 30271205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
